Abivax (AAVXF) Total Current Liabilities (2021 - 2026)

Abivax has reported Total Current Liabilities for 6 years, with the latest figure at $21.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 16.26% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $21.2 million, a 16.26% decrease from a year earlier, with the FY2025 full-year figure at $19.8 million, down 16.42% from the prior year.
• Total Current Liabilities was $21.2 million for Q1 2026 at Abivax, up from $19.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $29.5 million in Q3 2025, with the low at $1.8 million in Q4 2023.
• Average Total Current Liabilities over 5 years is $19.0 million, with a median of $21.2 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities tumbled 82.68% in 2023, then jumped 1231.93% in 2024.
• Over 5 years, Total Current Liabilities stood at $10.3 million in 2022, then plunged by 82.68% to $1.8 million in 2023, then surged by 1231.93% to $23.7 million in 2024, then declined by 16.42% to $19.8 million in 2025, then increased by 7.04% to $21.2 million in 2026.
• The last three Total Current Liabilities figures came in at $21.2 million (Q1 2026), $19.8 million (Q4 2025), and $29.5 million (Q3 2025), per Business Quant data.